Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02272855 · ClinicalTrials.gov registry record · Phase 2
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
A Phase 2 study of Malignant Melanoma, sponsored by Takara Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 8
- Study locations
NCT02272855: Completed Phase 2 study of Malignant Melanoma, sponsored by Takara Bio.
NCT02272855 is a Phase 2 study of Malignant Melanoma that has completed, run by Takara Bio. The registered enrollment target is 46 participants, below the 182-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (75% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02272855, a Phase 2 study of Malignant Melanoma, has completed, sponsored by Takara Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine if HF10 in combination with ipilimumab is effective in patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.
Conditions Studied
Interventions
- BIOLOGICAL HF10 plus Ipilimumab
Study Locations (8)
Pennsylvania
- Clinical Site - Bethlehem
- Clinical Site - Hershey
Texas
- Clinical Site - Dallas
- Clinical Site - Houston
California
- Clinical Site - San Francisco
Georgia
- Clinical Site - Atlanta
Oregon
- Clinical Site - Portland
Utah
- Clinical Site - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2014-04-30 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
What the finished NCT02272855 record still lists
NCT02272855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 182-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 1 intervention - of which HF10 plus Ipilimumab is the first listed.
NCT02272855 lists 8 locations in 6 states (Pennsylvania, Texas, California).
Frequently Asked Questions
What is clinical trial NCT02272855 about?
NCT02272855 is a clinical study titled "A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma". The purpose of this study is to determine if HF10 in combination with ipilimumab is effective in patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.
What is the current status of trial NCT02272855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2014-04-30. Estimated completion is 2018-08.
What conditions does trial NCT02272855 study?
This clinical trial studies the following conditions: Malignant Melanoma.
What interventions are being tested in trial NCT02272855?
The interventions under investigation include: HF10 plus Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02272855?
This trial is sponsored by Takara Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02272855 being conducted?
This trial has 8 study locations across California, Georgia, Oregon, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02272855's enrollment target sits among peer trials
46 16th of 28 higher than 13 of 28 other Malignant Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
RECRUITING · Phase 2
-
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Trial of Allovectin-7® for Metastatic Melanoma
COMPLETED · Phase 2
-
GM-CSF as Adjuvant Therapy of Melanoma
COMPLETED · Phase 2
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI